cyclodisone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 57513 |
| CHEMBL ID | 1994476 |
| SCHEMBL ID | 576075 |
| MeSH ID | M0138916 |
| Synonym |
|---|
| NCI60_003099 |
| nsc-348948 |
| 99591-73-8 |
| cyclodisone |
| nsc348948 |
| 1,5,2,4-dioxadithiepane, 2,2,4,4-tetraoxide |
| nsc 348948 |
| cyclic-soso |
| 1,5,2,4-dioxadithiepane 2,2,4,4-tetraoxide |
| 7yfv4wn79i , |
| 1,5,2,4-dioxadithiepane-2,2,4,4-tetraoxide |
| unii-7yfv4wn79i |
| SCHEMBL576075 |
| ethylene methanedisulfonate |
| CHEMBL1994476 |
| DTXSID80244147 |
| 1,5,2|e?,4|e?-dioxadithiepane-2,2,4,4-tetrone |
Cyclodisone is an active alkylating antitumor agent that is being considered for Phase 1 clinical trials in humans. It is currently undergoing toxicological evaluation.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cyclodisone is an active alkylating antitumor agent that is being considered for Phase 1 clinical trials in humans and is currently undergoing toxicological evaluation. " | ( Characterization of DNA damage and cytotoxicity induced in two human colon carcinoma cell lines by cyclodisone. Gibson, NW, 1989) | 1.94 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Cyclodisone, a cyclic sulfonate ester, was found to be more toxic to the BE cell line when compared with the HT-29 cell line." | ( Comparison of the in vitro cytotoxicity of cyclodisone with a series of structurally related analogues. Gibson, NW, 1988) | 1.45 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.51) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||